Skip to main content

New Leaf Ventures III, L.P.'s Form 4 filing

Harpoon Therapeutics, Inc. (HARP) · filed Aug 12, 2021

Accession no.
0000899243-21-032748
Filed
Aug 12, 2021, 4:15 PM ET
Trade date
Jan 11, 2021
Filing delay
213 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 1 non-derivative transaction. Open-market purchases total $4.00M. It was filed 213 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
New Leaf Ventures III, L.P.CIK 000162565310% Owner
New Leaf Venture Associates III, L.P.CIK 000162565610% Owner
New Leaf Venture Management III, L.L.C.CIK 000162565710% Owner
New Leaf Biopharma Opportunities II, L.P.CIK 000173529310% Owner
New Leaf BPO Management II, L.L.CCIK 000174075510% Owner
New Leaf BPO Associates II, L.P.CIK 000174078310% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 11, 2021Common StockPPurchaseAcquired+235,294$17.00+$3,999,998913,860IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Remarks

As of the filing date of this Form 4, the NLV Funds, in the aggregate, beneficially own less than ten percent of the Issuer's outstanding common stock and are no longer subject to Section 16.

Read the full filing on SEC EDGAR (opens in a new tab)